The Menopause Market was valued at USD 17.79 billion in 2024, and is projected to reach USD 24.35 billion by 2030, rising at a CAGR of 5.42%. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps. ![Menopause Market]( "Menopause Market")
The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.
The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.
The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.
The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.
The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.
The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.
Menopause Market Report Highlights
- Based on treatment, the dietary supplements treatment segment dominated the market in 2024 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
- The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
- North America held the largest revenue share in 2024. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
- In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
- In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.1.1. Segment scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Menopause Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. A growing number of women experiencing menopause
3.2.1.2. Increasing awareness regarding the treatment of menopausal symptoms
3.2.1.3. Innovation in products available for the management of Menopause
3.2.1.4. Increasing research supporting the advantages of dietary supplements
3.2.2. Market restraint analysis
3.2.2.1. Social stigma associated with menopause and adverse effects of products
3.2.2.2. Lack of well-defined regulations
3.3. Qualitative Analysis Impact of COVID-19 on Menopause Market
3.4. List of Products
3.5. Business Environment Analysis
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrants
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.1.1. Parent market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. A growing number of women experiencing menopause
3.2.1.2. Increasing awareness regarding the treatment of menopausal symptoms
3.2.1.3. Innovation in products available for the management of Menopause
3.2.1.4. Increasing research supporting the advantages of dietary supplements
3.2.2. Market restraint analysis
3.2.2.1. Social stigma associated with menopause and adverse effects of products
3.2.2.2. Lack of well-defined regulations
3.3. Qualitative Analysis Impact of COVID-19 on Menopause Market
3.4. List of Products
3.5. Business Environment Analysis
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrants
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
Chapter 4. Menopause Market Segment Analysis, By Treatment, 2018-2030 (USD Million)
4.1. Menopause Market: Treatment Movement Analysis and Market Share
4.2. Menopause Market: Treatment Segment Dashboard
4.3. Dietary Supplements
4.3.1. Dietary supplements market, 2018-2030 (USD Million)
4.4. OTC Pharma Products
4.4.1. OTC pharma products market, 2018-2030 (USD Million)
4.4.2. Hormonal Products
4.4.2.1. Hormonal products market, 2018-2030 (USD Million)
4.4.3. Non-hormonal products
4.4.3.1. Non-hormonal products market, 2018-2030 (USD Million)
4.2. Menopause Market: Treatment Segment Dashboard
4.3. Dietary Supplements
4.3.1. Dietary supplements market, 2018-2030 (USD Million)
4.4. OTC Pharma Products
4.4.1. OTC pharma products market, 2018-2030 (USD Million)
4.4.2. Hormonal Products
4.4.2.1. Hormonal products market, 2018-2030 (USD Million)
4.4.3. Non-hormonal products
4.4.3.1. Non-hormonal products market, 2018-2030 (USD Million)
Chapter 5. Region, By Treatment, 2018-2030 (USD Million)
5.1. Regional Market Dashboard
5.2. Regional marketplace: Key takeaways
5.3. North America
5.3.1. North America dietary supplements market
5.3.1.1. North America dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.3.2. North America OTC pharma products market
5.3.2.1. North America OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.3.3. U.S.
5.3.3.1. U.S. menopausal women target population (45 to 60 years), 2018-2023 in millions
5.3.3.2. U.S. dietary supplements market
5.3.3.2.1. Regulatory scenario
5.3.3.2.2. Competitive insights
5.3.3.2.3. U.S. dietary supplements market, 2018-2030 (USD Million)
5.3.3.3. U.S. OTC pharma products market
5.3.3.3.1. Regulatory scenario
5.3.3.3.2. Competitive insights
5.3.3.3.3. U.S. OTC pharma products market, 2018-2030 (USD Million)
5.3.4. Canada
5.3.4.1. Canada menopausal women target population (45 to 60 years), 2018-2023 in millions
5.3.4.2. Canada dietary supplements market
5.3.4.2.1. Regulatory scenario
5.3.4.2.2. Competitive insights
5.3.4.2.3. Canada dietary supplements market, 2018-2030 (USD Million)
5.3.4.3. Canada OTC pharma products market
5.3.4.3.1. Regulatory scenario
5.3.4.3.2. Competitive insights
5.3.4.3.3. Canada OTC pharma products market, 2018-2030 (USD Million)
5.3.5. Mexico
5.3.5.1. Mexico menopausal women target population (45 to 60 years), 2018-2023 in millions
5.3.5.2. Mexico dietary supplements market
5.3.5.2.1. Regulatory scenario
5.3.5.2.2. Competitive insights
5.3.5.2.3. Mexico dietary supplements market, 2018-2030 (USD Million)
5.3.5.3. Mexico OTC pharma products market
5.3.5.3.1. Regulatory scenario
5.3.5.3.2. Competitive insights
5.3.5.3.3. Mexico OTC pharma products market, 2018-2030 (USD Million)
5.4. Europe
5.4.1. Europe dietary supplements market
5.4.1.1. Europe dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.4.2. Europe OTC pharma products market
5.4.2.1. Europe OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.4.3. UK
5.4.3.1. Canada menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.3.2. Canada dietary supplements market
5.4.3.2.1. Regulatory scenario
5.4.3.2.2. Competitive insights
5.4.3.2.3. Canada dietary supplements market, 2018-2030 (USD Million)
5.4.3.3. Canada OTC pharma products market
5.4.3.3.1. Regulatory scenario
5.4.3.3.2. Competitive insights
5.4.3.3.3. Canada OTC pharma products market, 2018-2030 (USD Million)
5.4.4. Germany
5.4.4.1. Germany menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.4.2. Germany dietary supplements market
5.4.4.2.1. Regulatory scenario
5.4.4.2.2. Competitive insights
5.4.4.2.3. Germany dietary supplements market, 2018-2030 (USD Million)
5.4.4.3. Germany OTC pharma products market
5.4.4.3.1. Regulatory scenario
5.4.4.3.2. Competitive insights
5.4.4.3.3. Germany OTC pharma products market, 2018-2030 (USD Million)
5.4.5. France
5.4.5.1. France menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.5.2. France dietary supplements market
5.4.5.2.1. Regulatory scenario
5.4.5.2.2. Competitive insights
5.4.5.2.3. France dietary supplements market, 2018-2030 (USD Million)
5.4.5.3. France OTC pharma products market
5.4.5.3.1. Regulatory scenario
5.4.5.3.2. Competitive insights
5.4.5.3.3. France OTC pharma products market, 2018-2030 (USD Million)
5.4.6. Italy
5.4.6.1. Italy menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.6.2. Italy dietary supplements market
5.4.6.2.1. Regulatory scenario
5.4.6.2.2. Competitive insights
5.4.6.2.3. Italy dietary supplements market, 2018-2030 (USD Million)
5.4.6.3. Italy OTC pharma products market
5.4.6.3.1. Regulatory scenario
5.4.6.3.2. Competitive insights
5.4.6.3.3. Italy OTC pharma products market, 2018-2030 (USD Million)
5.4.7. Spain
5.4.7.1. Spain menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.7.2. Spain dietary supplements market
5.4.7.2.1. Regulatory scenario
5.4.7.2.2. Competitive insights
5.4.7.2.3. Spain dietary supplements market, 2018-2030 (USD Million)
5.4.7.3. Spain OTC pharma products market
5.4.7.3.1. Regulatory scenario
5.4.7.3.2. Competitive insights
5.4.7.3.3. Spain OTC pharma products market, 2018-2030 (USD Million)
5.4.8. Austria
5.4.8.1. Austria menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.8.2. Austria dietary supplements market
5.4.8.2.1. Regulatory scenario
5.4.8.2.2. Competitive insights
5.4.8.2.3. Austria dietary supplements market, 2018-2030 (USD Million)
5.4.8.3. Austria OTC pharma products market
5.4.8.3.1. Regulatory scenario
5.4.8.3.2. Competitive insights
5.4.8.3.3. Austria OTC pharma products market, 2018-2030 (USD Million)
5.4.9. Norway
5.4.9.1. Norway menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.9.2. Norway dietary supplements market
5.4.9.2.1. Regulatory scenario
5.4.9.2.2. Competitive insights
5.4.9.2.3. Norway dietary supplements market, 2018-2030 (USD Million)
5.4.9.3. Norway OTC pharma products market
5.4.9.3.1. Regulatory scenario
5.4.9.3.2. Competitive insights
5.4.9.3.3. Norway OTC pharma products market, 2018-2030 (USD Million)
5.4.10. Sweden
5.4.10.1. Sweden menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.10.2. Sweden dietary supplements market
5.4.10.2.1. Regulatory scenario
5.4.10.2.2. Competitive insights
5.4.10.2.3. Sweden dietary supplements market, 2018-2030 (USD Million)
5.4.10.3. Sweden OTC pharma products market
5.4.10.3.1. Regulatory scenario
5.4.10.3.2. Competitive insights
5.4.10.3.3. Sweden OTC pharma products market, 2018-2030 (USD Million)
5.4.11. Denmark
5.4.11.1. Denmark menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.11.2. Denmark dietary supplements market
5.4.11.2.1. Regulatory scenario
5.4.11.2.2. Competitive insights
5.4.11.2.3. Denmark dietary supplements market, 2018-2030 (USD Million)
5.4.11.3. Denmark OTC pharma products market
5.4.11.3.1. Regulatory scenario
5.4.11.3.2. Competitive insights
5.4.11.3.3. Denmark OTC pharma products market, 2018-2030 (USD Million)
5.5. Asia Pacific
5.5.1. Asia Pacific dietary supplements market
5.5.1.1. Asia Pacific dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.5.2. Asia Pacific OTC pharma products market
5.5.2.1. Asia Pacific OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.5.3. Japan
5.5.3.1. Japan menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.3.2. Japan dietary supplements market
5.5.3.2.1. Regulatory scenario
5.5.3.2.2. Competitive insights
5.5.3.2.3. Japan dietary supplements market, 2018-2030 (USD Million)
5.5.3.3. Japan OTC pharma products market
5.5.3.3.1. Regulatory scenario
5.5.3.3.2. Competitive insights
5.5.3.3.3. Japan OTC pharma products market, 2018-2030 (USD Million)
5.5.4. China
5.5.4.1. China menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.4.2. China dietary supplements market
5.5.4.2.1. Regulatory scenario
5.5.4.2.2. Competitive insights
5.5.4.2.3. China dietary supplements market, 2018-2030 (USD Million)
5.5.4.3. China OTC pharma products market
5.5.4.3.1. Regulatory scenario
5.5.4.3.2. Competitive insights
5.5.4.3.3. China OTC pharma products market, 2018-2030 (USD Million)
5.5.5. India
5.5.5.1. India menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.5.2. India dietary supplements market
5.5.5.2.1. Regulatory scenario
5.5.5.2.2. Competitive insights
5.5.5.2.3. India dietary supplements market, 2018-2030 (USD Million)
5.5.5.3. India OTC pharma products market
5.5.5.3.1. Regulatory scenario
5.5.5.3.2. Competitive insights
5.5.5.3.3. India OTC pharma products market, 2018-2030 (USD Million)
5.5.6. Australia
5.5.6.1. Australia menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.6.2. Australia dietary supplements market
5.5.6.2.1. Regulatory scenario
5.5.6.2.2. Competitive insights
5.5.6.2.3. Australia dietary supplements market, 2018-2030 (USD Million)
5.5.6.3. Australia OTC pharma products market
5.5.6.3.1. Regulatory scenario
5.5.6.3.2. Competitive insights
5.5.6.3.3. Australia OTC pharma products market, 2018-2030 (USD Million)
5.5.7. South Korea
5.5.7.1. South Korea menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.7.2. South Korea dietary supplements market
5.5.7.2.1. Regulatory scenario
5.5.7.2.2. Competitive insights
5.5.7.2.3. South Korea dietary supplements market, 2018-2030 (USD Million)
5.5.7.3. South Korea OTC pharma products market
5.5.7.3.1. Regulatory scenario
5.5.7.3.2. Competitive insights
5.5.7.3.3. South Korea OTC pharma products market, 2018-2030 (USD Million)
5.5.8. Thailand
5.5.8.1. Thailand menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.8.2. Thailand dietary supplements market
5.5.8.2.1. Regulatory scenario
5.5.8.2.2. Competitive insights
5.5.8.2.3. Thailand dietary supplements market, 2018-2030 (USD Million)
5.5.8.3. Thailand OTC pharma products market
5.5.8.3.1. Regulatory scenario
5.5.8.3.2. Competitive insights
5.5.8.3.3. Thailand OTC pharma products market, 2018-2030 (USD Million)
5.5.9. Taiwan
5.5.9.1. Taiwan menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.9.2. Taiwan dietary supplements market
5.5.9.2.1. Regulatory scenario
5.5.9.2.2. Competitive insights
5.5.9.2.3. Taiwan dietary supplements market, 2018-2030 (USD Million)
5.5.9.3. Taiwan OTC pharma products market
5.5.9.3.1. Regulatory scenario
5.5.9.3.2. Competitive insights
5.5.9.3.3. Taiwan OTC pharma products market, 2018-2030 (USD Million)
5.5.10. Malaysia
5.5.10.1. Malaysia menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.10.2. Malaysia dietary supplements market
5.5.10.2.1. Regulatory scenario
5.5.10.2.2. Competitive insights
5.5.10.2.3. Malaysia dietary supplements market, 2018-2030 (USD Million)
5.5.10.3. Malaysia OTC pharma products market
5.5.10.3.1. Regulatory scenario
5.5.10.3.2. Competitive insights
5.5.10.3.3. Malaysia OTC pharma products market, 2018-2030 (USD Million)
5.5.11. Singapore
5.5.11.1. Singapore menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.11.2. Singapore dietary supplements market
5.5.11.2.1. Regulatory scenario
5.5.11.2.2. Competitive insights
5.5.11.2.3. Singapore dietary supplements market, 2018-2030 (USD Million)
5.5.11.3. Singapore OTC pharma products market
5.5.11.3.1. Regulatory scenario
5.5.11.3.2. Competitive insights
5.5.11.3.3. Singapore OTC pharma products market, 2018-2030 (USD Million)
5.5.12. Vietnam
5.5.12.1. Vietnam menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.12.2. Vietnam dietary supplements market
5.5.12.2.1. Regulatory scenario
5.5.12.2.2. Competitive insights
5.5.12.2.3. Vietnam dietary supplements market, 2018-2030 (USD Million)
5.5.12.3. Vietnam OTC pharma products market
5.5.12.3.1. Regulatory scenario
5.5.12.3.2. Competitive insights
5.5.12.3.3. Vietnam OTC pharma products market, 2018-2030 (USD Million)
5.5.13. Hong Kong
5.5.13.1. Hong Kong menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.13.2. Hong Kong dietary supplements market
5.5.13.2.1. Regulatory scenario
5.5.13.2.2. Competitive insights
5.5.13.2.3. Hong Kong dietary supplements market, 2018-2030 (USD Million)
5.5.13.3. Hong Kong OTC pharma products market
5.5.13.3.1. Regulatory scenario
5.5.13.3.2. Competitive insights
5.5.13.3.3. Hong Kong OTC pharma products market, 2018-2030 (USD Million)
5.6. Latin America
5.6.1. Latin America dietary supplements market
5.6.1.1. Latin America dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.6.2. Latin America OTC pharma products market
5.6.2.1. Latin America OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.6.3. Brazil
5.6.3.1. Brazil menopausal women target population (45 to 60 years), 2018-2023 in millions
5.6.3.2. Brazil dietary supplements market
5.6.3.2.1. Regulatory scenario
5.6.3.2.2. Competitive insights
5.6.3.2.3. Brazil dietary supplements market, 2018-2030 (USD Million)
5.6.3.3. Brazil OTC pharma products market
5.6.3.3.1. Regulatory scenario
5.6.3.3.2. Competitive insights
5.6.3.3.3. Brazil OTC pharma products market, 2018-2030 (USD Million)
5.6.4. Argentina
5.6.4.1. Argentina menopausal women target population (45 to 60 years), 2018-2023 in millions
5.6.4.2. Argentina dietary supplements market
5.6.4.2.1. Regulatory scenario
5.6.4.2.2. Competitive insights
5.6.4.2.3. Argentina dietary supplements market, 2018-2030 (USD Million)
5.6.4.3. Argentina OTC pharma products market
5.6.4.3.1. Regulatory scenario
5.6.4.3.2. Competitive insights
5.6.4.3.3. Argentina OTC pharma products market, 2018-2030 (USD Million)
5.7. MEA
5.7.1. MEA dietary supplements market
5.7.1.1. MEA dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.7.2. MEA OTC pharma products market
5.7.2.1. MEA OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.7.3. South Africa
5.7.3.1. South Africa menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.3.2. South Africa dietary supplements market
5.7.3.2.1. Regulatory scenario
5.7.3.2.2. Competitive insights
5.7.3.2.3. South Africa dietary supplements market, 2018-2030 (USD Million)
5.7.3.3. South Africa OTC pharma products market
5.7.3.3.1. Regulatory scenario
5.7.3.3.2. Competitive insights
5.7.3.3.3. South Africa OTC pharma products market, 2018-2030 (USD Million)
5.7.4. Saudi Arabia
5.7.4.1. Saudi Arabia menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.4.2. Saudi Arabia dietary supplements market
5.7.4.2.1. Regulatory scenario
5.7.4.2.2. Competitive insights
5.7.4.2.3. Saudi Arabia dietary supplements market, 2018-2030 (USD Million)
5.7.4.3. Saudi Arabia OTC pharma products market
5.7.4.3.1. Regulatory scenario
5.7.4.3.2. Competitive insights
5.7.4.3.3. Saudi Arabia OTC pharma products market, 2018-2030 (USD Million)
5.7.5. UAE
5.7.5.1. UAE menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.5.2. UAE dietary supplements market
5.7.5.2.1. Regulatory scenario
5.7.5.2.2. Competitive insights
5.7.5.2.3. UAE dietary supplements market, 2018-2030 (USD Million)
5.7.5.3. UAE OTC pharma products market
5.7.5.3.1. Regulatory scenario
5.7.5.3.2. Competitive insights
5.7.5.3.3. UAE OTC pharma products market, 2018-2030 (USD Million)
5.7.6. Kuwait
5.7.6.1. Kuwait menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.6.2. Kuwait dietary supplements market
5.7.6.2.1. Regulatory scenario
5.7.6.2.2. Competitive insights
5.7.6.2.3. Kuwait dietary supplements market, 2018-2030 (USD Million)
5.7.6.3. Kuwait OTC pharma products market
5.7.6.3.1. Regulatory scenario
5.7.6.3.2. Competitive insights
5.7.6.3.3. Kuwait OTC pharma products market, 2018-2030 (USD Million)
5.2. Regional marketplace: Key takeaways
5.3. North America
5.3.1. North America dietary supplements market
5.3.1.1. North America dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.3.2. North America OTC pharma products market
5.3.2.1. North America OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.3.3. U.S.
5.3.3.1. U.S. menopausal women target population (45 to 60 years), 2018-2023 in millions
5.3.3.2. U.S. dietary supplements market
5.3.3.2.1. Regulatory scenario
5.3.3.2.2. Competitive insights
5.3.3.2.3. U.S. dietary supplements market, 2018-2030 (USD Million)
5.3.3.3. U.S. OTC pharma products market
5.3.3.3.1. Regulatory scenario
5.3.3.3.2. Competitive insights
5.3.3.3.3. U.S. OTC pharma products market, 2018-2030 (USD Million)
5.3.4. Canada
5.3.4.1. Canada menopausal women target population (45 to 60 years), 2018-2023 in millions
5.3.4.2. Canada dietary supplements market
5.3.4.2.1. Regulatory scenario
5.3.4.2.2. Competitive insights
5.3.4.2.3. Canada dietary supplements market, 2018-2030 (USD Million)
5.3.4.3. Canada OTC pharma products market
5.3.4.3.1. Regulatory scenario
5.3.4.3.2. Competitive insights
5.3.4.3.3. Canada OTC pharma products market, 2018-2030 (USD Million)
5.3.5. Mexico
5.3.5.1. Mexico menopausal women target population (45 to 60 years), 2018-2023 in millions
5.3.5.2. Mexico dietary supplements market
5.3.5.2.1. Regulatory scenario
5.3.5.2.2. Competitive insights
5.3.5.2.3. Mexico dietary supplements market, 2018-2030 (USD Million)
5.3.5.3. Mexico OTC pharma products market
5.3.5.3.1. Regulatory scenario
5.3.5.3.2. Competitive insights
5.3.5.3.3. Mexico OTC pharma products market, 2018-2030 (USD Million)
5.4. Europe
5.4.1. Europe dietary supplements market
5.4.1.1. Europe dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.4.2. Europe OTC pharma products market
5.4.2.1. Europe OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.4.3. UK
5.4.3.1. Canada menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.3.2. Canada dietary supplements market
5.4.3.2.1. Regulatory scenario
5.4.3.2.2. Competitive insights
5.4.3.2.3. Canada dietary supplements market, 2018-2030 (USD Million)
5.4.3.3. Canada OTC pharma products market
5.4.3.3.1. Regulatory scenario
5.4.3.3.2. Competitive insights
5.4.3.3.3. Canada OTC pharma products market, 2018-2030 (USD Million)
5.4.4. Germany
5.4.4.1. Germany menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.4.2. Germany dietary supplements market
5.4.4.2.1. Regulatory scenario
5.4.4.2.2. Competitive insights
5.4.4.2.3. Germany dietary supplements market, 2018-2030 (USD Million)
5.4.4.3. Germany OTC pharma products market
5.4.4.3.1. Regulatory scenario
5.4.4.3.2. Competitive insights
5.4.4.3.3. Germany OTC pharma products market, 2018-2030 (USD Million)
5.4.5. France
5.4.5.1. France menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.5.2. France dietary supplements market
5.4.5.2.1. Regulatory scenario
5.4.5.2.2. Competitive insights
5.4.5.2.3. France dietary supplements market, 2018-2030 (USD Million)
5.4.5.3. France OTC pharma products market
5.4.5.3.1. Regulatory scenario
5.4.5.3.2. Competitive insights
5.4.5.3.3. France OTC pharma products market, 2018-2030 (USD Million)
5.4.6. Italy
5.4.6.1. Italy menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.6.2. Italy dietary supplements market
5.4.6.2.1. Regulatory scenario
5.4.6.2.2. Competitive insights
5.4.6.2.3. Italy dietary supplements market, 2018-2030 (USD Million)
5.4.6.3. Italy OTC pharma products market
5.4.6.3.1. Regulatory scenario
5.4.6.3.2. Competitive insights
5.4.6.3.3. Italy OTC pharma products market, 2018-2030 (USD Million)
5.4.7. Spain
5.4.7.1. Spain menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.7.2. Spain dietary supplements market
5.4.7.2.1. Regulatory scenario
5.4.7.2.2. Competitive insights
5.4.7.2.3. Spain dietary supplements market, 2018-2030 (USD Million)
5.4.7.3. Spain OTC pharma products market
5.4.7.3.1. Regulatory scenario
5.4.7.3.2. Competitive insights
5.4.7.3.3. Spain OTC pharma products market, 2018-2030 (USD Million)
5.4.8. Austria
5.4.8.1. Austria menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.8.2. Austria dietary supplements market
5.4.8.2.1. Regulatory scenario
5.4.8.2.2. Competitive insights
5.4.8.2.3. Austria dietary supplements market, 2018-2030 (USD Million)
5.4.8.3. Austria OTC pharma products market
5.4.8.3.1. Regulatory scenario
5.4.8.3.2. Competitive insights
5.4.8.3.3. Austria OTC pharma products market, 2018-2030 (USD Million)
5.4.9. Norway
5.4.9.1. Norway menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.9.2. Norway dietary supplements market
5.4.9.2.1. Regulatory scenario
5.4.9.2.2. Competitive insights
5.4.9.2.3. Norway dietary supplements market, 2018-2030 (USD Million)
5.4.9.3. Norway OTC pharma products market
5.4.9.3.1. Regulatory scenario
5.4.9.3.2. Competitive insights
5.4.9.3.3. Norway OTC pharma products market, 2018-2030 (USD Million)
5.4.10. Sweden
5.4.10.1. Sweden menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.10.2. Sweden dietary supplements market
5.4.10.2.1. Regulatory scenario
5.4.10.2.2. Competitive insights
5.4.10.2.3. Sweden dietary supplements market, 2018-2030 (USD Million)
5.4.10.3. Sweden OTC pharma products market
5.4.10.3.1. Regulatory scenario
5.4.10.3.2. Competitive insights
5.4.10.3.3. Sweden OTC pharma products market, 2018-2030 (USD Million)
5.4.11. Denmark
5.4.11.1. Denmark menopausal women target population (45 to 60 years), 2018-2023 in millions
5.4.11.2. Denmark dietary supplements market
5.4.11.2.1. Regulatory scenario
5.4.11.2.2. Competitive insights
5.4.11.2.3. Denmark dietary supplements market, 2018-2030 (USD Million)
5.4.11.3. Denmark OTC pharma products market
5.4.11.3.1. Regulatory scenario
5.4.11.3.2. Competitive insights
5.4.11.3.3. Denmark OTC pharma products market, 2018-2030 (USD Million)
5.5. Asia Pacific
5.5.1. Asia Pacific dietary supplements market
5.5.1.1. Asia Pacific dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.5.2. Asia Pacific OTC pharma products market
5.5.2.1. Asia Pacific OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.5.3. Japan
5.5.3.1. Japan menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.3.2. Japan dietary supplements market
5.5.3.2.1. Regulatory scenario
5.5.3.2.2. Competitive insights
5.5.3.2.3. Japan dietary supplements market, 2018-2030 (USD Million)
5.5.3.3. Japan OTC pharma products market
5.5.3.3.1. Regulatory scenario
5.5.3.3.2. Competitive insights
5.5.3.3.3. Japan OTC pharma products market, 2018-2030 (USD Million)
5.5.4. China
5.5.4.1. China menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.4.2. China dietary supplements market
5.5.4.2.1. Regulatory scenario
5.5.4.2.2. Competitive insights
5.5.4.2.3. China dietary supplements market, 2018-2030 (USD Million)
5.5.4.3. China OTC pharma products market
5.5.4.3.1. Regulatory scenario
5.5.4.3.2. Competitive insights
5.5.4.3.3. China OTC pharma products market, 2018-2030 (USD Million)
5.5.5. India
5.5.5.1. India menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.5.2. India dietary supplements market
5.5.5.2.1. Regulatory scenario
5.5.5.2.2. Competitive insights
5.5.5.2.3. India dietary supplements market, 2018-2030 (USD Million)
5.5.5.3. India OTC pharma products market
5.5.5.3.1. Regulatory scenario
5.5.5.3.2. Competitive insights
5.5.5.3.3. India OTC pharma products market, 2018-2030 (USD Million)
5.5.6. Australia
5.5.6.1. Australia menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.6.2. Australia dietary supplements market
5.5.6.2.1. Regulatory scenario
5.5.6.2.2. Competitive insights
5.5.6.2.3. Australia dietary supplements market, 2018-2030 (USD Million)
5.5.6.3. Australia OTC pharma products market
5.5.6.3.1. Regulatory scenario
5.5.6.3.2. Competitive insights
5.5.6.3.3. Australia OTC pharma products market, 2018-2030 (USD Million)
5.5.7. South Korea
5.5.7.1. South Korea menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.7.2. South Korea dietary supplements market
5.5.7.2.1. Regulatory scenario
5.5.7.2.2. Competitive insights
5.5.7.2.3. South Korea dietary supplements market, 2018-2030 (USD Million)
5.5.7.3. South Korea OTC pharma products market
5.5.7.3.1. Regulatory scenario
5.5.7.3.2. Competitive insights
5.5.7.3.3. South Korea OTC pharma products market, 2018-2030 (USD Million)
5.5.8. Thailand
5.5.8.1. Thailand menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.8.2. Thailand dietary supplements market
5.5.8.2.1. Regulatory scenario
5.5.8.2.2. Competitive insights
5.5.8.2.3. Thailand dietary supplements market, 2018-2030 (USD Million)
5.5.8.3. Thailand OTC pharma products market
5.5.8.3.1. Regulatory scenario
5.5.8.3.2. Competitive insights
5.5.8.3.3. Thailand OTC pharma products market, 2018-2030 (USD Million)
5.5.9. Taiwan
5.5.9.1. Taiwan menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.9.2. Taiwan dietary supplements market
5.5.9.2.1. Regulatory scenario
5.5.9.2.2. Competitive insights
5.5.9.2.3. Taiwan dietary supplements market, 2018-2030 (USD Million)
5.5.9.3. Taiwan OTC pharma products market
5.5.9.3.1. Regulatory scenario
5.5.9.3.2. Competitive insights
5.5.9.3.3. Taiwan OTC pharma products market, 2018-2030 (USD Million)
5.5.10. Malaysia
5.5.10.1. Malaysia menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.10.2. Malaysia dietary supplements market
5.5.10.2.1. Regulatory scenario
5.5.10.2.2. Competitive insights
5.5.10.2.3. Malaysia dietary supplements market, 2018-2030 (USD Million)
5.5.10.3. Malaysia OTC pharma products market
5.5.10.3.1. Regulatory scenario
5.5.10.3.2. Competitive insights
5.5.10.3.3. Malaysia OTC pharma products market, 2018-2030 (USD Million)
5.5.11. Singapore
5.5.11.1. Singapore menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.11.2. Singapore dietary supplements market
5.5.11.2.1. Regulatory scenario
5.5.11.2.2. Competitive insights
5.5.11.2.3. Singapore dietary supplements market, 2018-2030 (USD Million)
5.5.11.3. Singapore OTC pharma products market
5.5.11.3.1. Regulatory scenario
5.5.11.3.2. Competitive insights
5.5.11.3.3. Singapore OTC pharma products market, 2018-2030 (USD Million)
5.5.12. Vietnam
5.5.12.1. Vietnam menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.12.2. Vietnam dietary supplements market
5.5.12.2.1. Regulatory scenario
5.5.12.2.2. Competitive insights
5.5.12.2.3. Vietnam dietary supplements market, 2018-2030 (USD Million)
5.5.12.3. Vietnam OTC pharma products market
5.5.12.3.1. Regulatory scenario
5.5.12.3.2. Competitive insights
5.5.12.3.3. Vietnam OTC pharma products market, 2018-2030 (USD Million)
5.5.13. Hong Kong
5.5.13.1. Hong Kong menopausal women target population (45 to 60 years), 2018-2023 in millions
5.5.13.2. Hong Kong dietary supplements market
5.5.13.2.1. Regulatory scenario
5.5.13.2.2. Competitive insights
5.5.13.2.3. Hong Kong dietary supplements market, 2018-2030 (USD Million)
5.5.13.3. Hong Kong OTC pharma products market
5.5.13.3.1. Regulatory scenario
5.5.13.3.2. Competitive insights
5.5.13.3.3. Hong Kong OTC pharma products market, 2018-2030 (USD Million)
5.6. Latin America
5.6.1. Latin America dietary supplements market
5.6.1.1. Latin America dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.6.2. Latin America OTC pharma products market
5.6.2.1. Latin America OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.6.3. Brazil
5.6.3.1. Brazil menopausal women target population (45 to 60 years), 2018-2023 in millions
5.6.3.2. Brazil dietary supplements market
5.6.3.2.1. Regulatory scenario
5.6.3.2.2. Competitive insights
5.6.3.2.3. Brazil dietary supplements market, 2018-2030 (USD Million)
5.6.3.3. Brazil OTC pharma products market
5.6.3.3.1. Regulatory scenario
5.6.3.3.2. Competitive insights
5.6.3.3.3. Brazil OTC pharma products market, 2018-2030 (USD Million)
5.6.4. Argentina
5.6.4.1. Argentina menopausal women target population (45 to 60 years), 2018-2023 in millions
5.6.4.2. Argentina dietary supplements market
5.6.4.2.1. Regulatory scenario
5.6.4.2.2. Competitive insights
5.6.4.2.3. Argentina dietary supplements market, 2018-2030 (USD Million)
5.6.4.3. Argentina OTC pharma products market
5.6.4.3.1. Regulatory scenario
5.6.4.3.2. Competitive insights
5.6.4.3.3. Argentina OTC pharma products market, 2018-2030 (USD Million)
5.7. MEA
5.7.1. MEA dietary supplements market
5.7.1.1. MEA dietary supplements market estimates and forecast, 2018-2030 (USD million)
5.7.2. MEA OTC pharma products market
5.7.2.1. MEA OTC pharma products market estimates and forecast, 2018-2030 (USD million)
5.7.3. South Africa
5.7.3.1. South Africa menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.3.2. South Africa dietary supplements market
5.7.3.2.1. Regulatory scenario
5.7.3.2.2. Competitive insights
5.7.3.2.3. South Africa dietary supplements market, 2018-2030 (USD Million)
5.7.3.3. South Africa OTC pharma products market
5.7.3.3.1. Regulatory scenario
5.7.3.3.2. Competitive insights
5.7.3.3.3. South Africa OTC pharma products market, 2018-2030 (USD Million)
5.7.4. Saudi Arabia
5.7.4.1. Saudi Arabia menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.4.2. Saudi Arabia dietary supplements market
5.7.4.2.1. Regulatory scenario
5.7.4.2.2. Competitive insights
5.7.4.2.3. Saudi Arabia dietary supplements market, 2018-2030 (USD Million)
5.7.4.3. Saudi Arabia OTC pharma products market
5.7.4.3.1. Regulatory scenario
5.7.4.3.2. Competitive insights
5.7.4.3.3. Saudi Arabia OTC pharma products market, 2018-2030 (USD Million)
5.7.5. UAE
5.7.5.1. UAE menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.5.2. UAE dietary supplements market
5.7.5.2.1. Regulatory scenario
5.7.5.2.2. Competitive insights
5.7.5.2.3. UAE dietary supplements market, 2018-2030 (USD Million)
5.7.5.3. UAE OTC pharma products market
5.7.5.3.1. Regulatory scenario
5.7.5.3.2. Competitive insights
5.7.5.3.3. UAE OTC pharma products market, 2018-2030 (USD Million)
5.7.6. Kuwait
5.7.6.1. Kuwait menopausal women target population (45 to 60 years), 2018-2023 in millions
5.7.6.2. Kuwait dietary supplements market
5.7.6.2.1. Regulatory scenario
5.7.6.2.2. Competitive insights
5.7.6.2.3. Kuwait dietary supplements market, 2018-2030 (USD Million)
5.7.6.3. Kuwait OTC pharma products market
5.7.6.3.1. Regulatory scenario
5.7.6.3.2. Competitive insights
5.7.6.3.3. Kuwait OTC pharma products market, 2018-2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.4. Company Profiles
6.4.1. Bayer AG
6.4.1.1. Company overview
6.4.1.2. Financial performance
6.4.1.3. Product benchmarking
6.4.1.4. Strategic initiatives
6.4.2. Theramex
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Product benchmarking
6.4.2.4. Strategic initiatives
6.4.3. AbbVie, Inc.
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Product benchmarking
6.4.3.4. Strategic initiatives
6.4.4. Pure Encapsulations, LLC
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Product benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Dr. Reddy’s Laboratories Ltd.
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Product benchmarking
6.4.5.4. Strategic initiatives
6.4.6. ReNew Life Holdings Corporation
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Product benchmarking
6.4.6.4. Strategic initiatives
6.4.7. Padagis
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Product benchmarking
6.4.7.4. Strategic initiatives
6.2. Company Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.4. Company Profiles
6.4.1. Bayer AG
6.4.1.1. Company overview
6.4.1.2. Financial performance
6.4.1.3. Product benchmarking
6.4.1.4. Strategic initiatives
6.4.2. Theramex
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Product benchmarking
6.4.2.4. Strategic initiatives
6.4.3. AbbVie, Inc.
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Product benchmarking
6.4.3.4. Strategic initiatives
6.4.4. Pure Encapsulations, LLC
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Product benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Dr. Reddy’s Laboratories Ltd.
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Product benchmarking
6.4.5.4. Strategic initiatives
6.4.6. ReNew Life Holdings Corporation
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Product benchmarking
6.4.6.4. Strategic initiatives
6.4.7. Padagis
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Product benchmarking
6.4.7.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global menopause market, by treatment, 2018-2030 (USD Million)
Table 4 Global menopause market, by region, 2018-2030 (USD Million)
Table 5 North America menopause market, by country, 2018-2030 (USD Million)
Table 6 North America menopause market, by treatment, 2018-2030 (USD Million)
Table 7 US menopause market, by treatment, 2018-2030 (USD Million)
Table 8 Canada menopause market, by treatment, 2018-2030 (USD Million)
Table 9 Mexico menopause market, by treatment, 2018-2030 (USD Million)
Table 10 Europe menopause market, by country, 2018-2030 (USD Million)
Table 11 Europe menopause market, by treatment, 2018-2030 (USD Million)
Table 12 Germany menopause market, by treatment, 2018-2030 (USD Million)
Table 13 UK menopause market, by treatment, 2018-2030 (USD Million)
Table 14 France menopause market, by treatment, 2018-2030 (USD Million)
Table 15 Italy menopause market, by treatment, 2018-2030 (USD Million)
Table 16 Spain menopause market, by treatment, 2018-2030 (USD Million)
Table 17 Norway menopause market, by treatment, 2018-2030 (USD Million)
Table 18 Sweden menopause market, by treatment, 2018-2030 (USD Million)
Table 19 Denmark menopause market, by treatment, 2018-2030 (USD Million)
Table 20 Asia Pacific menopause market, by country, 2018-2030 (USD Million)
Table 21 Asia Pacific menopause market, by treatment, 2018-2030 (USD Million)
Table 22 China menopause market, by treatment, 2018-2030 (USD Million)
Table 23 Japan menopause market, by treatment, 2018-2030 (USD Million)
Table 24 India menopause market, by treatment, 2018-2030 (USD Million)
Table 25 Australia menopause market, by treatment, 2018-2030 (USD Million)
Table 26 South Korea menopause market, by treatment, 2018-2030 (USD Million)
Table 27 Thailand menopause market, by treatment, 2018-2030 (USD Million)
Table 28 Latin America menopause market, by country, 2018-2030 (USD Million)
Table 29 Latin America menopause market, by treatment, 2018-2030 (USD Million)
Table 30 Brazil menopause market, by treatment, 2018-2030 (USD Million)
Table 31 Argentina menopause market, by treatment, 2018-2030 (USD Million)
Table 32 Middle East & Africa menopause market, by country, 2018-2030 (USD Million)
Table 33 Middle East & Africa menopause market, by treatment, 2018-2030 (USD Million)
Table 34 South Africa menopause market, by treatment, 2018-2030 (USD Million)
Table 35 Saudi Arabia menopause market, by treatment, 2018-2030 (USD Million)
Table 36 UAE menopause market, by treatment, 2018-2030 (USD Million)
Table 37 Kuwait menopause market, by treatment, 2018-2030 (USD Million)
Table 38 List of products containing. Rheum Raponticum (Siberian Rhubarb Root), Soy isoflavones, Black Cohosh, Red Clover and Amberen
Table 39 Regulatory scenario for new product approval in Mexico
Table 40 Regulations for health food filing and registration in China
Table 41 New health food filing system in China
Table 42 Regulatory scenario for new product approval in Brazil
Table 2 List of abbreviations
Table 3 Global menopause market, by treatment, 2018-2030 (USD Million)
Table 4 Global menopause market, by region, 2018-2030 (USD Million)
Table 5 North America menopause market, by country, 2018-2030 (USD Million)
Table 6 North America menopause market, by treatment, 2018-2030 (USD Million)
Table 7 US menopause market, by treatment, 2018-2030 (USD Million)
Table 8 Canada menopause market, by treatment, 2018-2030 (USD Million)
Table 9 Mexico menopause market, by treatment, 2018-2030 (USD Million)
Table 10 Europe menopause market, by country, 2018-2030 (USD Million)
Table 11 Europe menopause market, by treatment, 2018-2030 (USD Million)
Table 12 Germany menopause market, by treatment, 2018-2030 (USD Million)
Table 13 UK menopause market, by treatment, 2018-2030 (USD Million)
Table 14 France menopause market, by treatment, 2018-2030 (USD Million)
Table 15 Italy menopause market, by treatment, 2018-2030 (USD Million)
Table 16 Spain menopause market, by treatment, 2018-2030 (USD Million)
Table 17 Norway menopause market, by treatment, 2018-2030 (USD Million)
Table 18 Sweden menopause market, by treatment, 2018-2030 (USD Million)
Table 19 Denmark menopause market, by treatment, 2018-2030 (USD Million)
Table 20 Asia Pacific menopause market, by country, 2018-2030 (USD Million)
Table 21 Asia Pacific menopause market, by treatment, 2018-2030 (USD Million)
Table 22 China menopause market, by treatment, 2018-2030 (USD Million)
Table 23 Japan menopause market, by treatment, 2018-2030 (USD Million)
Table 24 India menopause market, by treatment, 2018-2030 (USD Million)
Table 25 Australia menopause market, by treatment, 2018-2030 (USD Million)
Table 26 South Korea menopause market, by treatment, 2018-2030 (USD Million)
Table 27 Thailand menopause market, by treatment, 2018-2030 (USD Million)
Table 28 Latin America menopause market, by country, 2018-2030 (USD Million)
Table 29 Latin America menopause market, by treatment, 2018-2030 (USD Million)
Table 30 Brazil menopause market, by treatment, 2018-2030 (USD Million)
Table 31 Argentina menopause market, by treatment, 2018-2030 (USD Million)
Table 32 Middle East & Africa menopause market, by country, 2018-2030 (USD Million)
Table 33 Middle East & Africa menopause market, by treatment, 2018-2030 (USD Million)
Table 34 South Africa menopause market, by treatment, 2018-2030 (USD Million)
Table 35 Saudi Arabia menopause market, by treatment, 2018-2030 (USD Million)
Table 36 UAE menopause market, by treatment, 2018-2030 (USD Million)
Table 37 Kuwait menopause market, by treatment, 2018-2030 (USD Million)
Table 38 List of products containing. Rheum Raponticum (Siberian Rhubarb Root), Soy isoflavones, Black Cohosh, Red Clover and Amberen
Table 39 Regulatory scenario for new product approval in Mexico
Table 40 Regulations for health food filing and registration in China
Table 41 New health food filing system in China
Table 42 Regulatory scenario for new product approval in Brazil
List of Figures
Figure 1 Menopause market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Commodity flow analysis
Figure 9 Menopause market snapshot
Figure 10 Menopause market segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Menopause market: Parent market outlook
Figure 13 Menopause market: Ancillary market outlook
Figure 14 Menopause market dynamics
Figure 15 Market driver relevance analysis (Current & future impact)
Figure 16 Market restraint relevance analysis (Current & future impact)
Figure 17 Menopause market: Porter’s five forces analysis
Figure 18 Menopause market: PESTLE analysis
Figure 19 Menopause market treatment outlook: Key takeaways
Figure 20 Menopause market: Treatment movement analysis, 2024 & 2030
Figure 21 Menopause dietary supplements market, 2018-2030 (USD Million)
Figure 22 Menopause OTC pharma products market, 2018-2030 (USD Million)
Figure 23 Menopause hormonal products market, 2018-2030 (USD Million)
Figure 24 Menopause non-hormonal products market, 2018-2030 (USD Million)
Figure 25 Menopause market revenue, by region
Figure 26 Regional key marketplace takeaways
Figure 27 Regional key marketplace takeaways
Figure 28 North America dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 29 North America OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 30 U.S. menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 31 U.S. dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 32 U.S. OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 33 Canada menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 34 Canada dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Canada OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Mexico menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 37 Mexico dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 38 Mexico OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 39 Europe dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Europe OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 41 UK menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 42 UK dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 43 UK OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Germany menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 45 Germany dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Germany OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 47 France menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 48 France dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 49 France OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 50 Italy menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 51 Italy dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 52 Italy OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 53 Spain menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 54 Spain dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 55 Spain OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 56 Austria menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 57 Austria dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 58 Austria OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 59 Denmark menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 60 Denmark dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 61 Denmark OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 62 Sweden menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 63 Sweden dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 64 Sweden OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 65 Norway menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 66 Norway dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 67 Norway OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 68 Asia Pacific dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 69 Asia Pacific OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 70 Japan menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 71 Japan dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 72 Japan OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 73 China menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 74 China dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 75 China OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 76 India menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 77 India dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 78 India OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 79 South Korea menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 80 South Korea dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 81 South Korea OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 82 Australia menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 83 Australia dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 84 Australia OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 85 Thailand menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 86 Thailand dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 87 Thailand OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 88 Taiwan menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 89 Taiwan dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 90 Taiwan OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 91 Malaysia menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 92 Malaysia dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 93 Malaysia OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 94 Singapore menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 95 Singapore dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 96 Singapore OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 97 Vietnam menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 98 Vietnam dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 99 Vietnam OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 100 Hong Kong menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 101 Hong Kong dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 102 Hong Kong OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 103 Latin dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 104 Latin America OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 105 Brazil menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 106 Brazil dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 107 Brazil OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 108 Argentina menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 109 Argentina dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 110 Argentina OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 111 MEA dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 112 MEA OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 113 South Africa menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 114 South Africa dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 115 South Africa OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 116 Saudi Arabia menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 117 Saudi Arabia dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 118 Saudi Arabia OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 119 UAE menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 120 UAE dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 121 UAE OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 122 Kuwait menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 123 Kuwait dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 124 Kuwait OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 125 Company categorization
Figure 126 Company market position analysis
Figure 127 Strategy mapping
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Commodity flow analysis
Figure 9 Menopause market snapshot
Figure 10 Menopause market segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Menopause market: Parent market outlook
Figure 13 Menopause market: Ancillary market outlook
Figure 14 Menopause market dynamics
Figure 15 Market driver relevance analysis (Current & future impact)
Figure 16 Market restraint relevance analysis (Current & future impact)
Figure 17 Menopause market: Porter’s five forces analysis
Figure 18 Menopause market: PESTLE analysis
Figure 19 Menopause market treatment outlook: Key takeaways
Figure 20 Menopause market: Treatment movement analysis, 2024 & 2030
Figure 21 Menopause dietary supplements market, 2018-2030 (USD Million)
Figure 22 Menopause OTC pharma products market, 2018-2030 (USD Million)
Figure 23 Menopause hormonal products market, 2018-2030 (USD Million)
Figure 24 Menopause non-hormonal products market, 2018-2030 (USD Million)
Figure 25 Menopause market revenue, by region
Figure 26 Regional key marketplace takeaways
Figure 27 Regional key marketplace takeaways
Figure 28 North America dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 29 North America OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 30 U.S. menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 31 U.S. dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 32 U.S. OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 33 Canada menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 34 Canada dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Canada OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Mexico menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 37 Mexico dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 38 Mexico OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 39 Europe dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Europe OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 41 UK menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 42 UK dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 43 UK OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Germany menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 45 Germany dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Germany OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 47 France menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 48 France dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 49 France OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 50 Italy menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 51 Italy dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 52 Italy OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 53 Spain menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 54 Spain dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 55 Spain OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 56 Austria menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 57 Austria dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 58 Austria OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 59 Denmark menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 60 Denmark dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 61 Denmark OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 62 Sweden menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 63 Sweden dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 64 Sweden OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 65 Norway menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 66 Norway dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 67 Norway OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 68 Asia Pacific dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 69 Asia Pacific OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 70 Japan menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 71 Japan dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 72 Japan OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 73 China menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 74 China dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 75 China OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 76 India menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 77 India dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 78 India OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 79 South Korea menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 80 South Korea dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 81 South Korea OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 82 Australia menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 83 Australia dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 84 Australia OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 85 Thailand menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 86 Thailand dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 87 Thailand OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 88 Taiwan menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 89 Taiwan dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 90 Taiwan OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 91 Malaysia menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 92 Malaysia dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 93 Malaysia OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 94 Singapore menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 95 Singapore dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 96 Singapore OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 97 Vietnam menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 98 Vietnam dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 99 Vietnam OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 100 Hong Kong menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 101 Hong Kong dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 102 Hong Kong OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 103 Latin dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 104 Latin America OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 105 Brazil menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 106 Brazil dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 107 Brazil OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 108 Argentina menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 109 Argentina dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 110 Argentina OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 111 MEA dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 112 MEA OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 113 South Africa menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 114 South Africa dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 115 South Africa OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 116 Saudi Arabia menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 117 Saudi Arabia dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 118 Saudi Arabia OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 119 UAE menopausal women target population (45 to 60 years), 2018-2023 in Million
Figure 120 UAE dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 121 UAE OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 122 Kuwait menopausal women target population (45 to 60 years), 2018-2023 in millions
Figure 123 Kuwait dietary supplements market estimates and forecast, 2018-2030 (USD Million)
Figure 124 Kuwait OTC pharma products market estimates and forecast, 2018-2030 (USD Million)
Figure 125 Company categorization
Figure 126 Company market position analysis
Figure 127 Strategy mapping
Companies Mentioned
The major companies featured in this Menopause market report include:- Bayer AG
- Theramex
- AbbVie, Inc.
- Pure Encapsulations, LLC
- Dr. Reddy’s Laboratories Ltd.
- ReNew Life Holdings Corporation
- Padagis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 17.79 Billion |
| Forecasted Market Value ( USD | $ 24.35 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
